NO953033L - Stabile baktericid/permeabilitetsökende proteinprodukter og farmasöytiske preparater inneholdende disse - Google Patents

Stabile baktericid/permeabilitetsökende proteinprodukter og farmasöytiske preparater inneholdende disse

Info

Publication number: NO953033L
Authority: NO; Norway
Prior art keywords: residue; protein products; pharmaceutical preparations; preparations containing; increasing protein
Prior art date: 1993-02-02

Application number

NO953033A

Other languages

English (en)

Other versions

NO953033D0 (no

NO315705B1 (no

Inventor

Georgia Theofan

Arnold Horwitz

David Burke

Manik Baltaian

Lynn Grinna

Original Assignee

Xoma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-02-02

Filing date

1995-08-01

Publication date

1995-10-02

1995-08-01 Application filed by Xoma Corp filed Critical Xoma Corp

1995-08-01 Publication of NO953033D0 publication Critical patent/NO953033D0/no

1995-10-02 Publication of NO953033L publication Critical patent/NO953033L/no

2003-10-13 Publication of NO315705B1 publication Critical patent/NO315705B1/no

Links

230000000844 anti-bacterial effect Effects 0.000 title abstract 2
102000004169 proteins and genes Human genes 0.000 title abstract 2
108090000623 proteins and genes Proteins 0.000 title abstract 2
239000003899 bactericide agent Substances 0.000 title 1
230000035699 permeability Effects 0.000 title 1
239000000825 pharmaceutical preparation Substances 0.000 title 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
235000004279 alanine Nutrition 0.000 abstract 1
125000000539 amino acid group Chemical group 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
208000027096 gram-negative bacterial infections Diseases 0.000 abstract 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
235000018102 proteins Nutrition 0.000 abstract 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Physics & Mathematics (AREA)
Hematology (AREA)
Plant Pathology (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)

NO19953033A 1993-02-02 1995-08-01 Baktericid/permeabilitetsökende protein eller et fragment derav, DNA som koder for dette, autonomt replikerende DNA-vektor, vertscelle,fremgangsmåte for fremstilling av dette, hybrid fusjonsprotein, farmasöytiskpreparat, polypeptid for medisin NO315705B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/013,801 US5420019A (en)	1993-02-02	1993-02-02	Stable bactericidal/permeability-increasing protein muteins
PCT/US1994/001235 WO1994018323A1 (en)	1993-02-02	1994-02-02	Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same

Publications (3)

Publication Number	Publication Date
NO953033D0 NO953033D0 (no)	1995-08-01
NO953033L true NO953033L (no)	1995-10-02
NO315705B1 NO315705B1 (no)	2003-10-13

Family

ID=21761817

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO19953033A NO315705B1 (no)	1993-02-02	1995-08-01	Baktericid/permeabilitetsökende protein eller et fragment derav, DNA som koder for dette, autonomt replikerende DNA-vektor, vertscelle,fremgangsmåte for fremstilling av dette, hybrid fusjonsprotein, farmasöytiskpreparat, polypeptid for medisin
NO20023224A NO319156B1 (no)	1993-02-02	2002-07-03	DNA som koder for et biologisk aktivt fragment av baktericid/permeabilitetsokende protein, fremgangsmate for fremstilling av dette, samt farmasoytisk preparat inneholdende dette og isolert, biologisk aktivt fragment av baktericid/permeabilitetsokende protein.
NO20050998A NO20050998D0 (no)	1993-02-02	2005-02-24	DNA som koder for et biologisk aktivt fragment av baktericid/premeabilitetsokende protein fremgangsmate for fremstilling av dette, samt farmasoytisk preparat inneholdende dette

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
NO20023224A NO319156B1 (no)	1993-02-02	2002-07-03	DNA som koder for et biologisk aktivt fragment av baktericid/permeabilitetsokende protein, fremgangsmate for fremstilling av dette, samt farmasoytisk preparat inneholdende dette og isolert, biologisk aktivt fragment av baktericid/permeabilitetsokende protein.
NO20050998A NO20050998D0 (no)	1993-02-02	2005-02-24	DNA som koder for et biologisk aktivt fragment av baktericid/premeabilitetsokende protein fremgangsmate for fremstilling av dette, samt farmasoytisk preparat inneholdende dette

Country Status (19)

Country	Link
US (6)	US5420019A (no)
EP (3)	EP1013760B1 (no)
JP (4)	JP4139867B2 (no)
KR (1)	KR100361997B1 (no)
CN (1)	CN1142996C (no)
AT (3)	ATE363535T1 (no)
AU (1)	AU693089B2 (no)
CA (1)	CA2155004C (no)
DE (3)	DE69426019T2 (no)
DK (2)	DK0689592T3 (no)
ES (2)	ES2150983T3 (no)
FI (2)	FI112367B (no)
GR (1)	GR3034492T3 (no)
HK (1)	HK1014548A1 (no)
NO (3)	NO315705B1 (no)
NZ (1)	NZ262284A (no)
PT (2)	PT689592E (no)
WO (1)	WO1994018323A1 (no)
ZA (1)	ZA94703B (no)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5198541A (en) *	1987-08-11	1993-03-30	New York University	Dna encoding bactericidal/permeability-increasing proteins
US6265187B1 (en) *	1989-02-14	2001-07-24	Incyte Pharmaceuticals, Inc.	Recombinant endotoxin-neutralizing proteins
US5840836A (en) *	1989-02-17	1998-11-24	Bayer Corporation	Pancreatic islet cell antigens obtained by molecular cloning
US6811989B1 (en) *	1989-02-17	2004-11-02	Bayer Corporation	Pancreatic islet cell antigens obtained by molecular cloning
US6274348B1 (en)	1992-05-19	2001-08-14	Xoma Corporation	Methods for the preparation of positively charged proteins
AU4382193A (en) *	1992-05-19	1993-12-13	Xoma Corporation	BPI-immunoglobulin fusion proteins
US5420019A (en) *	1993-02-02	1995-05-30	Xoma Corporation	Stable bactericidal/permeability-increasing protein muteins
US6214789B1 (en)	1993-03-12	2001-04-10	Xoma Corporation	Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US5652332A (en) *	1993-03-12	1997-07-29	Xoma	Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
WO1994020128A1 (en) *	1993-03-12	1994-09-15	Xoma Corporation	Therapeutic uses of bactericidal/permeability increasing protein products
AU7175694A (en)	1993-06-17	1995-01-17	Xoma Corporation	Lipopolysaccharide binding protein derivatives
WO1995002414A1 (en) *	1993-07-14	1995-01-26	Xoma Corporation	Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
US5770561A (en) *	1993-07-14	1998-06-23	Xoma Corporation	Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
US6759203B1 (en)	1993-09-22	2004-07-06	Xoma Corporation	Method for quantifying BPI in body fluids
PT759774E (pt) *	1993-09-22	2002-11-29	Xoma Technology Ltd	Metodo para o tratamento de infeccoes bacterianas gram-negativas por administracao de um produto de proteina bactericida indutora da permeabilidade (bip) e de um antibiotico
CN1133634A (zh) *	1993-09-22	1996-10-16	爱克斯欧玛公司	定量体液中的bpi的方法
AU703211B2 (en) *	1994-01-14	1999-03-18	Xoma Corporation	Anti-fungal methods and materials
EP0754050B1 (en) *	1994-01-14	2002-06-26	XOMA Technology Ltd.	Anti gram positive bacterial methods and materials
US5447913A (en)	1994-03-11	1995-09-05	Xoma Corporation	Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5786324A (en) *	1994-03-24	1998-07-28	Regents Of The University Of Minnesota	Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5830860A (en) *	1994-03-24	1998-11-03	Regents Of The University Of Minnesota	Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5578568A (en) *	1994-04-22	1996-11-26	Xoma Corporation	Method of treating conditions associated with intestinal ischemia/reperfusion
US6271203B1 (en)	1994-07-07	2001-08-07	Xoma Corporation	Anti-protozoan methods and materials
US5646114A (en) *	1994-07-11	1997-07-08	Xoma Corporation	Anti-protozoan methods
WO1996014428A1 (en) *	1994-11-08	1996-05-17	Novagen, Inc.	Method for in vitro protein synthesis
US5494896A (en) *	1995-03-31	1996-02-27	Xoma Corporation	Method of treating conditions associated with burn injuries
JP2001520631A (ja) *	1995-07-20	2001-10-30	ゾーマコーポレイション	抗真菌性ペプチド
EP0861088A1 (en) *	1995-11-14	1998-09-02	Xoma Corporation	Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury
US5686414A (en) *	1995-11-14	1997-11-11	Xoma Corporation	Methods of treating conditions associated with corneal transplantation
US5856159A (en) *	1996-03-27	1999-01-05	Cytel Corporation	Production of galactosyltransferase
NZ332720A (en)	1996-05-10	2000-07-28	Xoma Corp	Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
US5741779A (en) *	1996-05-10	1998-04-21	Xoma Corporation	Antithrombotic materials and methods
CA2255539C (en) *	1996-05-23	2005-09-27	Xoma Corporation	Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
US6486125B1 (en)	1996-05-24	2002-11-26	Regents Of The University Of Minnesota	Synthesis of soluble β-sheet forming peptides
US5888973A (en)	1996-08-09	1999-03-30	Xoma Corporation	Anti-chlamydial uses of BPI protein products
US6482796B2 (en) *	1996-11-01	2002-11-19	Xoma Corporation	Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
CN1062564C (zh) *	1996-12-20	2001-02-28	周红	猪血中提纯杀菌性/通透性增加蛋白的方法
ATE291617T1 (de) *	1997-01-24	2005-04-15	Avi Biopharm Inc	Verfahren und konjugat zur behandlung von helicobacter pylori-infektionen
US6093573A (en) *	1997-06-20	2000-07-25	Xoma	Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
FR2767323B1 (fr) *	1997-08-12	2001-01-05	Synt Em	Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
US6013631A (en) *	1998-06-19	2000-01-11	Xoma Corporation	Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6156514A (en) *	1998-12-03	2000-12-05	Sunol Molecular Corporation	Methods for making recombinant cells
US6242219B1 (en)	1999-03-18	2001-06-05	Xoma (Us) Llc	Methods for recombinant peptide production
US6153584A (en) *	1999-04-01	2000-11-28	Levy; Ofer	Therapeutic uses of BPI protein products in BPI-deficient humans
US7041644B2 (en) *	1999-04-01	2006-05-09	Xoma Technology	Therapeutic uses of BPI protein products in BPI-deficient humans
WO2001025254A2 (en)	1999-10-04	2001-04-12	University Of Maryland Biotechnology Institute	Novel adjuvant comprising a lipopolysaccharide antagonist
AU2002241589B2 (en) *	2000-12-01	2007-07-19	Xoma Technology Ltd.	Modulation of pericyte proliferation using BPI protein products or BPI inhibitors
US20030049616A1 (en) *	2001-01-08	2003-03-13	Sydney Brenner	Enzymatic synthesis of oligonucleotide tags
WO2002070667A2 (en) *	2001-03-05	2002-09-12	Transtech Pharma, Inc.	High level insect expression of rage proteins
EP1572719A4 (en)	2002-02-20	2007-11-14	Univ Minnesota	PARTIAL PEPTIDE MIMETICS AND METHOD
JP2005521401A (ja) *	2002-03-27	2005-07-21	イミュネックス・コーポレーション	ポリペプチド産生を増加させる方法
DE60335794D1 (de)	2002-03-29	2011-03-03	Xoma Technology Ltd	Multigene vectoren und methoden für eine erhöhte expression von rekombinanten polypeptiden
US7906722B2 (en) *	2005-04-19	2011-03-15	Palo Alto Research Center Incorporated	Concentrating solar collector with solid optical element
EP1741440A1 (en)	2005-07-08	2007-01-10	Mellitus S.L.	Use of BPI protein for the treatment of disorders of the metabolism and cardiovascular disorders
EP2592148B1 (en)	2007-10-12	2018-09-12	F. Hoffmann-La Roche AG	Protein expression from multiple nucleic acids
US9770483B2 (en)	2011-04-05	2017-09-26	Dana-Farber Cancer Institute, Inc.	BPI and its congeners as radiation mitigators and radiation protectors
GB201319620D0 (en)	2013-11-06	2013-12-18	Norwegian University Of Science And Technology	Immunosuppressive agents and their use in therapy
GB201319621D0 (en)	2013-11-06	2013-12-18	Norwegian University Of Science And Technology	Antimicrobial agents and their use in therapy
NZ756132A (en)	2017-03-10	2022-02-25	Hoffmann La Roche	Method for producing multispecific antibodies

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4588585A (en) *	1982-10-19	1986-05-13	Cetus Corporation	Human recombinant cysteine depleted interferon-β muteins
US4853332A (en) *	1982-10-19	1989-08-01	Cetus Corporation	Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4518584A (en) *	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
US4816566A (en) *	1983-06-01	1989-03-28	Hoffmann-La Roche, Inc.	Polypeptides having interferon activity
US4879226A (en) *	1984-04-06	1989-11-07	Asahi Kasei Kogyo Kabushiki Kaisha	Novel human physiologically active polypeptide
US4677063A (en) *	1985-05-02	1987-06-30	Cetus Corporation	Human tumor necrosis factor
US4677064A (en) *	1984-11-09	1987-06-30	Cetus Corporation	Human tumor necrosis factor
US4959314A (en) *	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
US5206344A (en) *	1985-06-26	1993-04-27	Cetus Oncology Corporation	Interleukin-2 muteins and polymer conjugation thereof
US5198541A (en) *	1987-08-11	1993-03-30	New York University	Dna encoding bactericidal/permeability-increasing proteins
US5576292A (en) *	1987-08-11	1996-11-19	New York University	Biologically active bactericidal/permeability-increasing protein fragments
EP0652230B1 (en) *	1987-08-11	2005-12-14	New York University	Biologically active bactericidal/permeability-increasing protein fragments
US5308834A (en) *	1989-02-14	1994-05-03	Incyte Pharmaceuticals, Inc.	Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5234912A (en) *	1989-02-14	1993-08-10	Incyte Pharmaceuticals, Inc.	Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5089274A (en) *	1989-02-14	1992-02-18	Incyte Pharmaceuticals, Inc.	Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5770694A (en) *	1990-08-13	1998-06-23	Incyte Pharmaceuticals, Inc.	Genetically engineered BPI variant proteins
US5334584A (en) *	1989-02-14	1994-08-02	Incyte Pharamaceuticals, Inc.	Recombinant, non-glycosylated bpi protein and uses thereof
US5171739A (en) *	1989-02-14	1992-12-15	Incyte Pharmaceuticals, Inc.	Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5166322A (en) *	1989-04-21	1992-11-24	Genetics Institute	Cysteine added variants of interleukin-3 and chemical modifications thereof
WO1992009621A1 (en) *	1990-12-03	1992-06-11	New York University	Biologically active bactericidal/permeability-increasing protein fragments
EP0605653A4 (en) *	1991-09-26	1995-03-15	Incyte Pharma Inc	NEW LIPOSACCHARID BINDING PROTEIN (LBP).
HUT65528A (en) *	1991-10-31	1994-06-28	Lee	Electronic identifying system enabling automatized remote response
DK0642579T3 (da) *	1992-05-19	1999-10-18	Xoma Corp	Forbedrede fremgangsmåder til fremstilling af endotoxin-bindende proteiner
AU4382193A (en) *	1992-05-19	1993-12-13	Xoma Corporation	BPI-immunoglobulin fusion proteins
US5420019A (en) *	1993-02-02	1995-05-30	Xoma Corporation	Stable bactericidal/permeability-increasing protein muteins
CN1163264C (zh) *	1993-02-02	2004-08-25	爱克索马技术有限公司	改进的药物组合物
US5348942A (en) *	1993-03-12	1994-09-20	Xoma Corporation	Therapeutic uses of bactericidal/permeability increasing protein products
EP0690872B1 (en) *	1993-03-12	1998-08-05	Xoma Corporation	Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
WO1994020129A1 (en) *	1993-03-12	1994-09-15	Xoma Corporation	Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
WO1994020128A1 (en) *	1993-03-12	1994-09-15	Xoma Corporation	Therapeutic uses of bactericidal/permeability increasing protein products
EP0760849A1 (en) *	1993-04-30	1997-03-12	Incyte Pharmaceuticals, Inc.	Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof

1993
- 1993-02-02 US US08/013,801 patent/US5420019A/en not_active Expired - Lifetime
1994
- 1994-02-02 JP JP51821094A patent/JP4139867B2/ja not_active Expired - Fee Related
- 1994-02-02 KR KR1019950703197A patent/KR100361997B1/ko not_active IP Right Cessation
- 1994-02-02 ZA ZA94703A patent/ZA94703B/xx unknown
- 1994-02-02 DK DK94908704T patent/DK0689592T3/da active
- 1994-02-02 AT AT03000252T patent/ATE363535T1/de not_active IP Right Cessation
- 1994-02-02 DE DE69426019T patent/DE69426019T2/de not_active Expired - Lifetime
- 1994-02-02 DE DE69434980T patent/DE69434980T2/de not_active Expired - Fee Related
- 1994-02-02 AT AT94908704T patent/ATE196650T1/de not_active IP Right Cessation
- 1994-02-02 DE DE69431995T patent/DE69431995T2/de not_active Expired - Fee Related
- 1994-02-02 EP EP00103901A patent/EP1013760B1/en not_active Expired - Lifetime
- 1994-02-02 ES ES94908704T patent/ES2150983T3/es not_active Expired - Lifetime
- 1994-02-02 AU AU61702/94A patent/AU693089B2/en not_active Ceased
- 1994-02-02 NZ NZ262284A patent/NZ262284A/en not_active IP Right Cessation
- 1994-02-02 EP EP03000252A patent/EP1310558B1/en not_active Expired - Lifetime
- 1994-02-02 ES ES03000252T patent/ES2288199T3/es not_active Expired - Lifetime
- 1994-02-02 DK DK03000252T patent/DK1310558T3/da active
- 1994-02-02 EP EP94908704A patent/EP0689592B1/en not_active Expired - Lifetime
- 1994-02-02 PT PT94908704T patent/PT689592E/pt unknown
- 1994-02-02 WO PCT/US1994/001235 patent/WO1994018323A1/en active IP Right Grant
- 1994-02-02 CA CA2155004A patent/CA2155004C/en not_active Expired - Fee Related
- 1994-02-02 AT AT00103901T patent/ATE230797T1/de not_active IP Right Cessation
- 1994-02-02 CN CNB941916723A patent/CN1142996C/zh not_active Expired - Fee Related
- 1994-02-02 PT PT03000252T patent/PT1310558E/pt unknown
1995
- 1995-04-28 US US08/430,417 patent/US5674834A/en not_active Expired - Lifetime
- 1995-06-06 US US08/466,822 patent/US5827816A/en not_active Expired - Lifetime
- 1995-08-01 NO NO19953033A patent/NO315705B1/no not_active IP Right Cessation
- 1995-08-01 FI FI953658A patent/FI112367B/fi active
1998
- 1998-12-28 HK HK98115811A patent/HK1014548A1/xx not_active IP Right Cessation
1999
- 1999-10-19 US US09/425,034 patent/US6433140B1/en not_active Expired - Fee Related
2000
- 2000-09-28 GR GR20000402074T patent/GR3034492T3/el not_active IP Right Cessation
2002
- 2002-07-03 NO NO20023224A patent/NO319156B1/no unknown
- 2002-07-16 US US10/196,460 patent/US6828418B2/en not_active Expired - Fee Related
2003
- 2003-08-26 FI FI20031199A patent/FI115633B/fi active IP Right Grant
- 2003-10-15 JP JP2003355706A patent/JP2004024276A/ja not_active Withdrawn
2004
- 2004-03-31 JP JP2004108131A patent/JP2004254697A/ja not_active Withdrawn
- 2004-11-03 US US10/980,722 patent/US20060009383A1/en not_active Abandoned
2005
- 2005-02-24 NO NO20050998A patent/NO20050998D0/no not_active Application Discontinuation
2006
- 2006-07-26 JP JP2006204005A patent/JP2006321813A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP1013760A2 (en)	2000-06-28
DE69434980T2 (de)	2008-01-24
FI953658A0 (fi)	1995-08-01
ATE230797T1 (de)	2003-01-15
FI115633B (fi)	2005-06-15
ATE363535T1 (de)	2007-06-15
JP4139867B2 (ja)	2008-08-27
DK1310558T3 (da)	2007-10-08
FI112367B (fi)	2003-11-28
EP1310558A3 (en)	2003-08-13
PT1310558E (pt)	2007-09-07
JP2004254697A (ja)	2004-09-16
DK0689592T3 (da)	2000-10-16
NZ262284A (en)	1997-11-24
NO953033D0 (no)	1995-08-01
EP1310558A2 (en)	2003-05-14
FI20031199A (fi)	2003-08-26
US6828418B2 (en)	2004-12-07
ZA94703B (en)	1994-09-05
US20060009383A1 (en)	2006-01-12
DE69434980D1 (de)	2007-07-12
US5420019A (en)	1995-05-30
JPH08506586A (ja)	1996-07-16
JP2006321813A (ja)	2006-11-30
NO315705B1 (no)	2003-10-13
HK1014548A1 (en)	1999-09-30
US5674834A (en)	1997-10-07
CA2155004C (en)	2010-03-30
KR960700340A (ko)	1996-01-19
DE69431995D1 (de)	2003-02-13
PT689592E (pt)	2001-03-30
EP1013760B1 (en)	2003-01-08
AU6170294A (en)	1994-08-29
EP0689592B1 (en)	2000-09-27
NO20023224L (no)	1995-10-02
EP0689592A1 (en)	1996-01-03
CN1142996C (zh)	2004-03-24
US20030109436A1 (en)	2003-06-12
NO20050998L (no)	1995-10-02
US6433140B1 (en)	2002-08-13
CA2155004A1 (en)	1994-08-18
US5827816A (en)	1998-10-27
EP1310558B1 (en)	2007-05-30
DE69431995T2 (de)	2003-11-13
WO1994018323A1 (en)	1994-08-18
ES2150983T3 (es)	2000-12-16
NO20023224D0 (no)	2002-07-03
AU693089B2 (en)	1998-06-25
CN1120352A (zh)	1996-04-10
DE69426019D1 (de)	2000-11-02
KR100361997B1 (ko)	2003-04-08
GR3034492T3 (en)	2000-12-29
ES2288199T3 (es)	2008-01-01
FI953658A (fi)	1995-09-07
NO319156B1 (no)	2005-06-27
NO20050998D0 (no)	2005-02-24
EP1013760A3 (en)	2000-08-09
JP2004024276A (ja)	2004-01-29
ATE196650T1 (de)	2000-10-15
DE69426019T2 (de)	2001-05-17

Legal Events

Date	Code	Title	Description
2010-09-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO953033L (no)	1995-10-02	Stabile baktericid/permeabilitetsökende proteinprodukter og farmasöytiske preparater inneholdende disse
FI860153A (fi)	1986-07-17	Oligopeptider, deras mellanprodukter och foerfarande foer deras framstaellning.
MXPA03002218A (es)	2004-03-18	Peptidos antimicrobianos y metodos de uso.
PT711305E (pt)	2002-05-31	Protegrinas
IL85020A0 (en)	1988-06-30	Pancreatic secretory trypsin inhibitor and variants thereof,process expression vector and recombinant host therefor and pharmaceutical compositions containing it
ATE264913T1 (de)	2004-05-15	Protease-resistente analoge des thrombomodulin
ES2114555T3 (es)	1998-06-01	Nuevo interferon gamma humano recombinado.
ATE143974T1 (de)	1996-10-15	Peptide des hiv-gag proteins, ihre herstellung und verwendung
Theofan et al.	1996	Stable bactericidal/permeability-increasing protein muteins
DK547486A (da)	1987-06-17	Peptider samt praeparater indeholdende disse
BR0107799A (pt)	2002-10-22	Proteìna de interação de wt1 wtip